Page 4 - Daniel Drucker News Today

Research pioneer Dr. Daniel Drucker has much to be proud of, as the GLP-1-based diabetes drugs hailing from his early research are named 2023 breakthrough of the year by the Science Magazine.

GLP-1 agonists, commonly used to treat Type 2 diabetes and weight loss, may help lower the prevalence of heart disease, according to a study published in Cell Metabloism.

The finding suggests that weight loss and diabetes injections such Ozempic, Wegovy and Zepbound, may have wider medical benefits than first thought

The journal highlights their reduction of cardiovascular incidents and the possibilities they create for treating conditions as diverse as addictions, Alzheimer’s disease and Parkinson’s disease

Zealand Pharma has risen 63% in market value on the Copenhagen stock exchange this year compared with 40% for its larger and much more famous peer.

The success of semaglutide mimic drugs in helping people lose weight saw demand rocket in 2023, with manufacturers struggling to keep up - something that almost never happens

Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and clinical experts

CBC's Marketplace rounds up the consumer and health news you need from the week.

Despite widely publicized reports of rare but severe side effects, obesity doctors say Ozempic and drugs like it have the potential to vastly medical help for a chronic illness that patients have been forced for too long to try to cure on their own.

New data also shows a reduced rate of cardiovascular problems in some patients